Clinical Takeaway
In this phase 3 randomized controlled trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term follow-up extending to one year. This is among the most rigorous clinical investigations of a cannabis-based treatment for one of the most prevalent pain conditions globally, affecting over 500 million people. The trial design, including a randomized withdrawal phase, provides a meaningful opportunity to assess both sustained efficacy and the effects of discontinuation.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by evaluating a full-spectrum cannabis extract as a potential alternative to conventional analgesics and opioids for chronic low back pain, a condition affecting over 500 million people globally with suboptimal current treatment options. The study’s rigorous design with 820 participants and extended follow-up provides the highest level of evidence to date regarding cannabis-based medicine efficacy and safety in CLBP management. If VER-01 demonstrates superior efficacy and tolerability, it could substantially reduce opioid dependence and expand the pharmacologic armamentarium for patients with inadequate responses to standard interventions.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔬 This phase 3 trial of full-spectrum cannabis extract for chronic low back pain represents meaningful progress in an understudied therapeutic domain, with 820 participants providing reasonable statistical power to assess efficacy and safety over 12 weeks of double-blind treatment. However, several important caveats warrant consideration: the abstract does not specify the cannabinoid profile (THC and CBD ratios), dosing regimens, or primary outcome measures, all of which substantially influence both efficacy and tolerability in clinical practice. The 12-week treatment window reflects a reasonable timeframe for assessing pain reduction, though chronic pain management often requires longer observation to determine sustainability and identify delayed adverse effects. The inclusion of a 6-month open-label extension phase is valuable but introduces inherent bias, making it critical to examine the blinded phase A results independently before drawing conclusions about long-term utility. If this trial demonstrates meaningful pain reduction with an acceptable safety profile compared to placebo, particularly in patients who have failed conventional analgesics, it could offer